Skip to main content

Advertisement

SpringerLink
Log in

Cellular apoptosis susceptibility protein (CAS) suppresses the proliferation of breast cancer cells by upregulated cyp24a1

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Breast cancer is the most common cancer in women. Although several studies demonstrated cellular apoptosis susceptibility protein (CAS) involved in the development of breast cancer, the underlying mechanisms of CAS regulating cell processes in the breast cancer remain elusive. In the present study, we explored the possible mechanism of CAS in contributing to the cell proliferation in the breast cancer cell line MCF-7. Knockdown of CAS led to the reduction of cell viability and proliferation. Furthermore, cell cycle was arrested in G0/G1 phase after knocking down CAS with the decrease of cyclinD1. In addition, RNA-seq analysis for the CAS knockdown cells demonstrated that total eleven genes were significantly altered (Fold changes > 2). Of note, the expression of cyp24a1 was dramatically increased in the shCAS cells compared to that of shNC cells as well as confirmed by quantitative real-time polymerase chain reaction (qPCR). These observations clarified the previous conflicting results on the cell fates of the breast cells regulated by CAS and provide new insight into the role of CAS in the development of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Google Scholar 

  2. Zhan C, Zhang XY, Pang D. High expression of CSE1L is associated with poor prognosis in breast cancer. Int J Clin Exp Pathol. 2016;9(11):11788–94.

    CAS  Google Scholar 

  3. Yuksel UM, et al. Does CSE1L overexpression affect distant metastasis development in breast cancer? Oncol Res Treat. 2015;38(9):431–4.

    CAS  PubMed  Google Scholar 

  4. Lee WR, et al. CSE1L Links cAMP/PKA and Ras/ERK pathways and regulates the expressions and phosphorylations of ERK1/2, CREB, and MITF in melanoma cells. Mol Carcinog. 2016;55(11):1542–52.

    CAS  PubMed  Google Scholar 

  5. Cheng DD, et al. CSE1L interaction with MSH6 promotes osteosarcoma progression and predicts poor patient survival. Sci Rep. 2017;7(1):1–13.

    Google Scholar 

  6. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol. 2002;8(3):385–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Shiraki K, et al. Cellular apoptosis susceptibility protein and proliferation in human hepatocellular carcinoma. Int J Mol Med. 2006;18(1):77–81.

    CAS  PubMed  Google Scholar 

  8. Winkler J, et al. Cellular apoptosis susceptibility (CAS) is linked to integrin β1 and required for tumor cell migration and invasion in hepatocellular carcinoma (HCC). Oncotarget. 2016;7(16):22883–92.

    PubMed  PubMed Central  Google Scholar 

  9. Liu GM, et al. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer Cell Int. 2019;19:138.

    PubMed  PubMed Central  Google Scholar 

  10. Pimiento JM, et al. Knockdown of cse1l gene in colorectal cancer reduces tumorigenesis in vitro. Am J Pathol. 2016;186(10):2761–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Jiang MC, et al. CSE1L modulates Ras-induced cancer cell invasion: correlation of K-Ras mutation and CSE1L expression in colorectal cancer progression. Am J Surg. 2013;206(3):418–27.

    CAS  PubMed  Google Scholar 

  12. Tai CJ, Su TC, Jiang MC. Correlations between cytoplasmic CSE1L in neoplastic colorectal glands and depth of tumor penetration and cancer stage. J Transl Med. 2013;11:29.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Tsao TY, et al. Function of CSE1L/CAS in the secretion of HT-29 human colorectal cells and its expression in human colon. Mol Cell Biochem. 2009;327(1–2):163–70.

    CAS  PubMed  Google Scholar 

  14. Sillars-Hardebol AH, et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut. 2012;61(11):1568–75.

    CAS  PubMed  Google Scholar 

  15. Li KK, et al. MIR-137 suppresses growth and invasion, is downregulated in oligodendroglial tumors and targets CSE1L. Brain Pathol. 2013;23(4):426–39.

    CAS  PubMed  Google Scholar 

  16. Liu C, et al. CSE1L participates in regulating cell mitosis in human seminoma. Cell Prolif. 2018;52:e12549.

    PubMed  PubMed Central  Google Scholar 

  17. Liu J, et al. Expression of cellular apoptosis susceptibility (CAS) in the human testis and testicular germ cell tumors. Med Oncol. 2019;36(7):61.

    PubMed  Google Scholar 

  18. Lorenzato A, et al. The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C. FASEB J. 2012;26(6):2446–56.

    CAS  PubMed  Google Scholar 

  19. Dong Q, et al. Roles of the CSE1L-mediated nuclear import pathway in epigenetic silencing. Proc Natl Acad Sci USA. 2018;115(17):E4013–E40224022.

    CAS  PubMed  Google Scholar 

  20. Kutay U, et al. Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor. Cell. 1997;90(6):1061–71.

    CAS  PubMed  Google Scholar 

  21. Ewings KE, Ryan KM. Hzf and hCAS/CSE1L: making the right choice in p53-mediated tumour suppression. Cell Res. 2007;17(10):829–31.

    CAS  PubMed  Google Scholar 

  22. Tanaka T, et al. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell. 2007;130(4):638–50.

    CAS  PubMed  Google Scholar 

  23. Zhu JH, et al. Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells. Asian Pac J Cancer Prev. 2013;14(2):1017–21.

    PubMed  Google Scholar 

  24. Liao CF, et al. CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells. Mol Med. 2012;18:1269–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Xu R, et al. Highly-purified exosomes and shed microvesicles isolated from the human colon cancer cell line LIM1863 by sequential centrifugal ultrafiltration are biochemically and functionally distinct. Methods. 2015;87:11–25.

    CAS  PubMed  Google Scholar 

  26. Tai CJ, et al. Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis. J Exp Clin Cancer Res. 2010;29(1):110.

    PubMed  PubMed Central  Google Scholar 

  27. Bera TK, et al. Cse1l is essential for early embryonic growth and development. Mol Cell Biol. 2001;21(20):7020–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Yuksel UM, et al. The relationship between CSE1L expression and axillary lymph node metastasis in breast cancer. Tumori. 2015;101(2):194–8.

    CAS  PubMed  Google Scholar 

  29. Liu C, et al. CSE1L participates in regulating cell mitosis in human seminoma. Cell Prolif. 2019;52(2):e12549.

    PubMed  Google Scholar 

  30. Li Y, et al. CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF. J Cell Physiol. 2020;235(3):2071–9.

    CAS  PubMed  Google Scholar 

  31. Liao CF, et al. CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells. J Exp Clin Cancer Res. 2008;27:15.

    PubMed  PubMed Central  Google Scholar 

  32. Tang Z, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Gyorffy B, Schafer R. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat. 2009;118(3):433–41.

    PubMed  Google Scholar 

  34. Gyorffy B, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725–31.

    PubMed  Google Scholar 

  35. Mihaly Z, et al. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res Treat. 2013;140(2):219–32.

    CAS  PubMed  Google Scholar 

  36. Chandrashekar DS, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Tai CJ, et al. Increased cellular apoptosis susceptibility (CSE1L/CAS) protein expression promotes protrusion extension and enhances migration of MCF-7 breast cancer cells. Exp Cell Res. 2010;316(17):2969–81.

    CAS  PubMed  Google Scholar 

  38. Monian P, Jiang X. The cellular apoptosis susceptibility protein (CAS) promotes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis and cell proliferation. J Biol Chem. 2016;291(5):2379–88.

    CAS  PubMed  Google Scholar 

  39. Baldin V, et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7(5):812–21.

    CAS  PubMed  Google Scholar 

  40. Shivakumar L, et al. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol. 2002;22(12):4309–18.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Behrens P, et al. Implication of the proliferation and apoptosis associated CSE1L/CAS gene for breast cancer development. Anticancer Res. 2001;21(4A):2413–7.

    CAS  PubMed  Google Scholar 

  42. Tung MC, et al. Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1570–7.

    CAS  PubMed  Google Scholar 

  43. Ma S, et al. LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer. Aging. 2018;10(8):2062–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Luo W, et al. 24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics. J Steroid Biochem Mol Biol. 2013;136:252–7.

    CAS  PubMed  Google Scholar 

  45. Horvath HC, et al. The candidate oncogene CYP24A1: a potential biomarker for colorectal tumorigenesis. J Histochem Cytochem. 2010;58(3):277–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Chen G, et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res. 2011;17(4):817–26.

    CAS  PubMed  Google Scholar 

  47. Sakakia T, et al. CYP24A1 as a potential target for cancer therapy. Anticancer Agents Med Chem. 2014;14:97–108.

    Google Scholar 

  48. Zhalehjoo N, Shakiba Y, Panjehpour M. Gene expression profiles of CYP24A1 and CYP27B1 in malignant and normal breast tissues. Mol Med Rep. 2017;15(1):467–73.

    CAS  PubMed  Google Scholar 

  49. Osanai M, Lee GH. CYP24A1-induced vitamin D insufficiency promotes breast cancer growth. Oncol Rep. 2016;36(5):2755–62.

    CAS  PubMed  Google Scholar 

  50. Tourigny A, et al. CYP24A1 exacerbated activity during diabetes contributes to kidney tubular apoptosis via caspase-3 increased expression and activation. PLoS ONE. 2012;7(10):e48652.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Mohri T, et al. MicroRNA regulates human vitamin D receptor. Int J Cancer. 2009;125(6):1328–33.

    CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported in part by grants from the National Key Research and Development Program of China (No. 2018YFC1003602 to HC); National Natural Science Foundation of China (81671432 and 81871202 to HC) and the startup R&D funding of Nantong University (03083011 and 03083028 to HC).

Author information

Author notes

  1. Mei Ye and Ruigang Han have equally contribution.

Authors and Affiliations

  1. School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China

    Mei Ye, Xunda Wang, Allan Z. Zhao, Fanghong Li & Hao Chen

  2. Reproductive Medicine Center of The 306th Hospital of PLA, Beijing, China

    Ruigang Han

  3. Institute of Reproductive Medicine, Medical School of Nantong University, Nantong University, Nantong, China

    Jianwu Shi & Hao Chen

Authors
  1. Mei Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruigang Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianwu Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xunda Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Allan Z. Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fanghong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HC conceived and designed the experiments. MY and XDW performed the experiments and analyzed the data. AZZ and FHL gave intelligent advice, JWS revised the manuscript, and MY, RGH and HC wrote the paper.

Corresponding authors

Correspondence to Fanghong Li or Hao Chen.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest for this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Hao Chen is the primary corresponding author.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 15 kb)

Supplementary file2 (PDF 288 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ye, M., Han, R., Shi, J. et al. Cellular apoptosis susceptibility protein (CAS) suppresses the proliferation of breast cancer cells by upregulated cyp24a1. Med Oncol 37, 43 (2020). https://doi.org/10.1007/s12032-020-01366-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-020-01366-w

Keywords

Search

Navigation